8 results about "Factor XI" patented technology

The present disclosure provides methods for using antibodies that bind to Factor XI (FXI) for the purpose of preventing or treating clot formation or thrombogenesis after a surgical procedure. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting PT. As such, these antagonist antibodies may be used to treat or prevent clot formation in a subject requiring such treatment, such as, but not limited to, post-surgery.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

This disclosure relates to dosage regimens for combination therapies comprising anti-Factor XI and / or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof, e.g., for use in the treatment of thromboembolic disorders or related conditions.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

This invention relates to the field of pharmaceutical biology and discloses a single-domain antibody against coagulation factor XI (FXI) and its derived protein. Specifically, this invention discloses a coagulation factor XI (FXI) binding protein derived from a single-domain antibody against coagulation factor XI (FXI) and its uses.

The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human Factor XI and activated Factor XI ("Factor XIa"), as well as to pharmaceutical compositions and treatment methods comprising them.

The invention relates to the field of medical biology, and discloses a single-domain antibody aiming at a blood coagulation factor XI (FXI) and a derived protein thereof. Specifically, the invention discloses a blood coagulation factor XI (FXI) binding protein derived from a single domain antibody aiming at the blood coagulation factor XI (FXI) and application of the blood coagulation factor XI (FXI) binding protein.